Episode Details

The UK government has accepted all 44 recommendations for regulating AI in healthcare, marking a major policy shift for the MHRA. As of October 6, 2026, the UK is moving from a single pre-market approval to a lifecycle-based regulatory approach for AI-enabled medical devices. This episode breaks down what this new framework means for manufacturers, including the immediate opening of applications for Phase 3 of the AI Airlock sandbox, an upcoming applicant webinar on October 22, 2026, and the MHRA's commitment to release draft guidance on managing AI device changes by December 2026. We discuss the implications for post-market surveillance and provide actionable steps for regulatory, quality, and market-access teams. Key Questions: - What did the UK government announce on October 6, 2026, regarding AI in healthcare? - How is the MHRA's approach to regulating AI-enabled medical devices changing? - What is the new "lifecycle-based" regulatory model, and how does it differ from traditional pre-market approval? - What is the AI Airlock sandbox, and who is eligible for Phase 3? - When is the MHRA webinar for AI Airlock applicants? - What key deadline should manufacturers note for draft guidance on managing AI device changes? - How will this new framework impact post-market surveillance obligations for AI devices? - What immediate steps should developers of AI medical devices take to align with the new UK regulations? Sources: - https://www.gov.uk/government/news/government-backs-recommendations-of-nhs-doctors-led-ai-commission - https://www.gov.uk/government/publications/government-response-to-the-national-commissions-recommendations-on-the-regulation-of-ai-in-healthcare - https://www.digitalhealth.net/2026/10/government-accepts-all-44-nhs-ai-commission-recommendations/ - https://medtech.globaldata.com/News/article/uk-government-accepts-all-44-recommendations-to-monitor-medical-ai-throughout-its-use-81335 - https://www.healthtechworld.co.uk/news/uk-accepts-ai-commission-regs-as-mhra-opens-airlock-phase-3/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies navigating complex changes like the UK's new AI framework. Our experts offer end-to-end support, from developing a robust regulatory strategy for the new lifecycle approach to managing post-market surveillance obligations. We act as your local UK representative, ensuring continuous compliance and monitoring regulatory shifts that impact your market access. With our advanced AI tools and global network, we help you efficiently compile technical dossiers and maintain your presence in over 30 markets. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and database at https://pureglobal.ai.